Stock Track | Novo Nordisk Soars 10.16% Intraday After FDA Approves Wegovy Weight-Loss Pill

Stock Track12-23 22:49

Novo Nordisk A/S (NVO) saw its stock surge 10.16% during intraday trading on Tuesday, marking one of the most significant gains for the Danish pharmaceutical giant this year. The rally followed the U.S. Food and Drug Administration's (FDA) approval of the oral version of its blockbuster weight-loss drug, Wegovy.

The FDA's approval of the Wegovy pill is a major milestone for Novo Nordisk, positioning it as the first company to bring an oral GLP-1 weight-loss treatment to market. The pill is expected to launch in early January, priced at $149 per month for starter doses, making it more accessible to patients who prefer oral medications over injections. Analysts predict the pill could generate billions in sales, helping Novo Nordisk regain market share from rival Eli Lilly.

The approval comes after a challenging year for Novo Nordisk, which has faced stiff competition and supply constraints. The company's CEO, Mike Doustdar, emphasized the convenience of the pill, stating it could help patients achieve similar weight loss results as the injectable version. Investors are optimistic about the pill's potential to revitalize Novo Nordisk's growth trajectory in the lucrative obesity-drug market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1180162964?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 22:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180162964","market":"nz","top_or_hot":-1,"title":"Stock Track | Novo Nordisk Soars 10.16% Intraday After FDA Approves Wegovy Weight-Loss Pill","media":"Stock Track","content":"<p>Novo Nordisk A/S (NVO) saw its stock surge 10.16% during intraday trading on Tuesday, marking one of the most significant gains for the Danish pharmaceutical giant this year. The rally followed the U.S. Food and Drug Administration's (FDA) approval of the oral version of its blockbuster weight-loss drug, Wegovy.</p><p>The FDA's approval of the Wegovy pill is a major milestone for Novo Nordisk, positioning it as the first company to bring an oral GLP-1 weight-loss treatment to market. The pill is expected to launch in early January, priced at $149 per month for starter doses, making it more accessible to patients who prefer oral medications over injections. Analysts predict the pill could generate billions in sales, helping Novo Nordisk regain market share from rival Eli Lilly.</p><p>The approval comes after a challenging year for Novo Nordisk, which has faced stiff competition and supply constraints. The company's CEO, Mike Doustdar, emphasized the convenience of the pill, stating it could help patients achieve similar weight loss results as the injectable version. Investors are optimistic about the pill's potential to revitalize Novo Nordisk's growth trajectory in the lucrative obesity-drug market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Novo Nordisk Soars 10.16% Intraday After FDA Approves Wegovy Weight-Loss Pill</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Novo Nordisk Soars 10.16% Intraday After FDA Approves Wegovy Weight-Loss Pill\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-12-23 22:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Novo Nordisk A/S (NVO) saw its stock surge 10.16% during intraday trading on Tuesday, marking one of the most significant gains for the Danish pharmaceutical giant this year. The rally followed the U.S. Food and Drug Administration's (FDA) approval of the oral version of its blockbuster weight-loss drug, Wegovy.</p><p>The FDA's approval of the Wegovy pill is a major milestone for Novo Nordisk, positioning it as the first company to bring an oral GLP-1 weight-loss treatment to market. The pill is expected to launch in early January, priced at $149 per month for starter doses, making it more accessible to patients who prefer oral medications over injections. Analysts predict the pill could generate billions in sales, helping Novo Nordisk regain market share from rival Eli Lilly.</p><p>The approval comes after a challenging year for Novo Nordisk, which has faced stiff competition and supply constraints. The company's CEO, Mike Doustdar, emphasized the convenience of the pill, stating it could help patients achieve similar weight loss results as the injectable version. Investors are optimistic about the pill's potential to revitalize Novo Nordisk's growth trajectory in the lucrative obesity-drug market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVO","symbol_name":"诺和诺德","start_time":0,"source_url":"","article_id":"1180162964","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180162964","pubTimestamp":1766501342,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Novo Nordisk A/S (NVO) saw its stock surge 10.16% during intraday trading on Tuesday, marking one of the most significant gains for the Danish pharmaceutical giant this year. The rally followed the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVO":"诺和诺德"},"translate_title":"个股追踪|FDA批准Wegovy减肥药后诺和诺德盘中大涨10.16%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S (NVO) saw its stock surge 10.16% during intraday trading on Tuesday, marking one of the most significant gains for the Danish pharmaceutical giant this year. The rally followed the U.S. Food and Drug Administration's (FDA) approval of the oral version of its blockbuster weight-loss drug, Wegovy.The FDA's approval of the Wegovy pill is a major milestone for Novo Nordisk, positioning it as the first company to bring an oral GLP-1 weight-loss treatment to market. The pill is expected to launch in early January, priced at $149 per month for starter doses, making it more accessible to patients who prefer oral medications over injections. Analysts predict the pill could generate billions in sales, helping Novo Nordisk regain market share from rival Eli Lilly.The approval comes after a challenging year for Novo Nordisk, which has faced stiff competition and supply constraints. The company's CEO, Mike Doustdar, emphasized the convenience of the pill, stating it could help patients achieve similar weight loss results as the injectable version. Investors are optimistic about the pill's potential to revitalize Novo Nordisk's growth trajectory in the lucrative obesity-drug market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1180162964","isCrawlerRequest":true}